Torrent Pharmaceuticals Ltd's Q4FY25 Quarter Results
- 21 May 2025
Result Summary
- Torrent Pharmaceuticals Ltd reported a 2.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 11.0%.
- Its expenses for the quarter were down by 0.3% QoQ and up 3.8% YoY.
- The net profit decreased 10.7% QoQ and increased 56.4% YoY.
- The earnings per share (EPS) of Torrent Pharmaceuticals Ltd stood at 13.3 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 2776.00 | 2842.00 | 2500.00 | -2.3% | 11.0% |
Total Expenses | 2145.00 | 2151.00 | 2067.00 | -0.3% | 3.8% |
Profit Before Tax | 631.00 | 691.00 | 433.00 | -8.7% | 45.7% |
Tax | 182.00 | 188.00 | 146.00 | -3.2% | 24.7% |
Profit After Tax | 449.00 | 503.00 | 287.00 | -10.7% | 56.4% |
Earnings Per Share | 13.30 | 14.90 | 8.50 | -10.7% | 56.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Torrent Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, known for its focus on the development, manufacture, and marketing of a wide range of pharmaceutical products. The company's portfolio includes a variety of therapeutic segments, such as cardiovascular, central nervous system, gastrointestinal, and anti-infective drugs, among others. Torrent Pharmaceuticals has a significant presence in both domestic and international markets, contributing to its robust growth over the years. As of the latest available data, there are no major developments or changes in the company's operations that have been indicated. The company continues to focus on expanding its market reach and enhancing its product offerings.
Revenue
In Q4FY25, Torrent Pharmaceuticals Ltd reported a total income of ₹2,776 crore, marking a decrease from the previous quarter's income of ₹2,842 crore, which is a quarter-over-quarter (QoQ) decline of 2.3%. However, on a year-over-year (YoY) basis, the company achieved an increase of 11.0% compared to the ₹2,500 crore reported in Q4FY24. This growth suggests consistent expansion over the past year, despite the recent quarterly decrease. These revenue figures highlight the company's ability to sustain an upward trajectory over the longer term, even as it experiences fluctuations in shorter periods.
Profitability
For Q4FY25, Torrent Pharmaceuticals Ltd recorded a Profit Before Tax (PBT) of ₹631 crore, which represents an 8.7% decrease QoQ from ₹691 crore in Q3FY25. However, when compared to the same quarter in the previous year, where the PBT was ₹433 crore, there is a significant YoY growth of 45.7%. The Profit After Tax (PAT) for Q4FY25 was ₹449 crore, down by 10.7% from ₹503 crore in the preceding quarter, but up by 56.4% from ₹287 crore in Q4FY24. The company's tax expenditure in Q4FY25 amounted to ₹182 crore, slightly reduced by 3.2% QoQ from ₹188 crore in Q3FY25, while marking a YoY increase of 24.7% from ₹146 crore in Q4FY24.
Operating Metrics
The Earnings Per Share (EPS) for Q4FY25 stood at ₹13.30, reflecting a decline of 10.7% QoQ from ₹14.90 in Q3FY25, but an increase of 56.5% YoY from ₹8.50 in Q4FY24. This fluctuation in EPS aligns with the trends observed in the company's profitability metrics. In terms of expenses, the company reported total expenses of ₹2,145 crore in Q4FY25, slightly less by 0.3% from ₹2,151 crore in the previous quarter. When compared to Q4FY24's expenses of ₹2,067 crore, there is a YoY increase of 3.8%. These metrics provide insight into the company's operational efficiency and cost management over the different periods.